Literature DB >> 22516689

Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance.

Lorenza Venturini1, Maria Grazia Daidone, Rosita Motta, Graziella Cimino-Reale, Stacey F Hoare, Alessandro Gronchi, Marco Folini, William Nicol Keith, Nadia Zaffaroni.   

Abstract

This study investigated the prevalence and the prognostic relevance of the 2 known telomere maintenance mechanisms (TMMs), telomerase activity (TA) and alternative lengthening of telomeres (ALT), in malignant peripheral nerve sheath tumors (MPNST). In 57 specimens from 49 patients with MPNST (35 sporadic, 14 neurofibromatosis type 1-related), TA was determined using the telomeric repeat amplification protocol, and ALT was detected by assaying ALT-associated promyelocytic leukemia bodies (APB) and terminal restriction fragment (TRF) length distribution. TA or ALT (defined on the basis of APB) alone was found in 24.6% or 26.3% of the lesions, respectively, whereas 6 cases (10.5%) were TA+/ALT+. A concordance between APB and TRF results in defining the ALT status was observed in 44 of 57 cases (77.2%; P < .0001). TA was more frequently expressed in samples from patients with neurofibromatosis type 1 than in those with sporadic disease (60% vs 29.4%, P = 0.087). In the overall series, TA proved to be prognostic for 5-year disease-specific death (hazard ratio, 3.78; 95% confidence interval [CI], 1.60-8.95; P = .002), even when adjusted for the presence of neurofibromatosis type 1 (hazard ratio, 4.22; 95% CI, 1.804-9.874; P = .001) and margin status after surgery (hazard ratio, 5.78; 95% CI, 2.19-15.26; P < .001). Conversely, ALT did not significantly affect clinical outcome of MPNST using either APB expression (hazard ratio, 1.25; 95% CI 0.54-2.89; P = 0.605) or TRF distribution (hazard ratio, 0.57; 95% CI, 0.17-1.96; P = .375) as the detection approach. Our results indicate for the first time that both TMMs, TA and ALT, are present in MPNST and differentially affect patient prognosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22516689      PMCID: PMC3367852          DOI: 10.1093/neuonc/nos083

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  43 in total

1.  Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas.

Authors:  Gary A Ulaner; Andrew R Hoffman; Jesse Otero; Hsuan-Ying Huang; Zhiquan Zhao; Madhu Mazumdar; Richard Gorlick; Paul Meyers; John H Healey; Marc Ladanyi
Journal:  Genes Chromosomes Cancer       Date:  2004-10       Impact factor: 5.006

Review 2.  A survey of telomerase activity in human cancer.

Authors:  J W Shay; S Bacchetti
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

3.  Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution.

Authors:  Matteo Anghileri; Rosalba Miceli; Marco Fiore; Luigi Mariani; Andrea Ferrari; Chiara Mussi; Laura Lozza; Paola Collini; Patrizia Olmi; Paolo G Casali; Silvana Pilotti; Alessandro Gronchi
Journal:  Cancer       Date:  2006-09-01       Impact factor: 6.860

4.  A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.

Authors:  Jeremy D Henson; Jonathan A Hannay; Stanley W McCarthy; Janice A Royds; Thomas R Yeager; Robert A Robinson; Stephen B Wharton; David A Jellinek; Susan M Arbuckle; Jinyoung Yoo; Bruce G Robinson; Diana L Learoyd; Paul D Stalley; S Fiona Bonar; Dihua Yu; Raphael E Pollock; Roger R Reddel
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

5.  Telomerase activity and telomere length in human ovarian cancer and melanoma cell lines: correlation with sensitivity to DNA damaging agents.

Authors:  R Villa; M Folini; P Perego; R Supino; E Setti; M G Daidone; F Zunino; N Zaffaroni
Journal:  Int J Oncol       Date:  2000-05       Impact factor: 5.650

6.  Multiple mechanisms of telomere maintenance exist in liposarcomas.

Authors:  Jay E Johnson; Robert J Varkonyi; Jaclyn Schwalm; Ryan Cragle; Andres Klein-Szanto; Arthur Patchefsky; Edna Cukierman; Margaret von Mehren; Dominique Broccoli
Journal:  Clin Cancer Res       Date:  2005-08-01       Impact factor: 12.531

Review 7.  Malignant peripheral nerve sheath tumors.

Authors:  Richard G Perrin; Abhijit Guha
Journal:  Neurosurg Clin N Am       Date:  2004-04       Impact factor: 2.509

8.  Specific association of human telomerase activity with immortal cells and cancer.

Authors:  N W Kim; M A Piatyszek; K R Prowse; C B Harley; M D West; P L Ho; G M Coviello; W E Wright; S L Weinrich; J W Shay
Journal:  Science       Date:  1994-12-23       Impact factor: 47.728

Review 9.  Schwannoma (neurilemoma) with malignant transformation. A rare, distinctive peripheral nerve tumor.

Authors:  J M Woodruff; A M Selig; K Crowley; P W Allen
Journal:  Am J Surg Pathol       Date:  1994-09       Impact factor: 6.394

10.  Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.

Authors:  Pascale Lévy; Dominique Vidaud; Karen Leroy; Ingrid Laurendeau; Janine Wechsler; Giulia Bolasco; Béatrice Parfait; Pierre Wolkenstein; Michel Vidaud; Ivan Bièche
Journal:  Mol Cancer       Date:  2004-07-15       Impact factor: 27.401

View more
  11 in total

1.  TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors.

Authors:  Hendrikus J Dubbink; Hannah Bakels; Edward Post; Ellen C Zwarthoff; Robert M Verdijk
Journal:  J Neurooncol       Date:  2014-07-18       Impact factor: 4.130

2.  ALTernative Telomere Maintenance and Cancer.

Authors:  Robert L Dilley; Roger A Greenberg
Journal:  Trends Cancer       Date:  2015-10-01

3.  miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells.

Authors:  Graziella Cimino-Reale; Paolo Gandellini; Francesca Santambrogio; Marta Recagni; Nadia Zaffaroni; Marco Folini
Journal:  J Hematol Oncol       Date:  2017-07-17       Impact factor: 17.388

Review 4.  Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT).

Authors:  Marco De Vitis; Francesco Berardinelli; Antonella Sgura
Journal:  Int J Mol Sci       Date:  2018-02-18       Impact factor: 5.923

5.  Telomerase Dysfunction in the Tumorigenesis of Genetic Disorders.

Authors:  Maha Mohamed Farid Aql; Seham Abd-El Ghafour Bahget; Naglaa Kholoussi; Ghada Mohamed El Hossiny Abdel-Salam; Haiam Abdel Raouf; Maha Mohamed Eid; Rania El-Bialy Esmail
Journal:  Int J Mol Cell Med       Date:  2021-05-22

6.  TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.

Authors:  Christian Koelsche; Marcus Renner; Wolfgang Hartmann; Regine Brandt; Burkhard Lehner; Nina Waldburger; Ingo Alldinger; Thomas Schmitt; Gerlinde Egerer; Roland Penzel; Eva Wardelmann; Peter Schirmacher; Andreas von Deimling; Gunhild Mechtersheimer
Journal:  J Exp Clin Cancer Res       Date:  2014-04-11

Review 7.  Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition.

Authors:  Lynnette R Ferguson; Helen Chen; Andrew R Collins; Marisa Connell; Giovanna Damia; Santanu Dasgupta; Meenakshi Malhotra; Alan K Meeker; Amedeo Amedei; Amr Amin; S Salman Ashraf; Katia Aquilano; Asfar S Azmi; Dipita Bhakta; Alan Bilsland; Chandra S Boosani; Sophie Chen; Maria Rosa Ciriolo; Hiromasa Fujii; Gunjan Guha; Dorota Halicka; William G Helferich; W Nicol Keith; Sulma I Mohammed; Elena Niccolai; Xujuan Yang; Kanya Honoki; Virginia R Parslow; Satya Prakash; Sarallah Rezazadeh; Rodney E Shackelford; David Sidransky; Phuoc T Tran; Eddy S Yang; Christopher A Maxwell
Journal:  Semin Cancer Biol       Date:  2015-04-11       Impact factor: 17.012

Review 8.  The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype.

Authors:  João P Amorim; Gustavo Santos; João Vinagre; Paula Soares
Journal:  Genes (Basel)       Date:  2016-09-19       Impact factor: 4.096

Review 9.  Telomere Maintenance Mechanisms in Cancer.

Authors:  Tiago Bordeira Gaspar; Ana Sá; José Manuel Lopes; Manuel Sobrinho-Simões; Paula Soares; João Vinagre
Journal:  Genes (Basel)       Date:  2018-05-03       Impact factor: 4.096

Review 10.  The Role of Alternative Lengthening of Telomeres Mechanism in Cancer: Translational and Therapeutic Implications.

Authors:  Marta Recagni; Joanna Bidzinska; Nadia Zaffaroni; Marco Folini
Journal:  Cancers (Basel)       Date:  2020-04-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.